FY results shy of consensus FY EBITDA came in at EUR119m, 5% below cons. Restated for restructuring costs, EBITDA was EUR236m, up 22% yoy, with EBITDA margin above co. guidance (14.9% vs 14.4%). EBITDA growth was mostly explained by positive volumes and mix excl. France (+EUR21m) and price increases notably on X-ray products (EUR14.6m). France was penalized by the implementation of a new distribution policy driven by public bodies (EBITDA in France fell by EUR2.4m). EBIT was 17% below cons. wit ....